Cytisine - Achieve Life Sciences

Drug Profile

Cytisine - Achieve Life Sciences

Alternative Names: Tabex

Latest Information Update: 21 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sopharma
  • Developer Achieve Life Sciences; National Center for Complementary and Integrative Health
  • Class Alkaloids; Smoking cessation therapies
  • Mechanism of Action Alpha4 beta2 nicotinic receptor agonists; Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Smoking withdrawal

Highest Development Phases

  • Phase III Smoking withdrawal

Most Recent Events

  • 20 Feb 2018 Preliminary efficacy, pharmacokinetics and adverse events data from a phase I/II trial in Smoking withdrawal (In volunteers) released by Achieve Life Sciences
  • 24 Jan 2018 Achieve Life Sciences and University of Bristol extend their licensing agreement for cytisine-based therapies for Smoking withdrawal
  • 28 Nov 2017 Achieve Life Sciences and Auckland UniServices enter into clinical trial supply agreement for cytisine in New Zealand for Smoking withdrawal
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top